Quick answer: Continuous glucose monitoring (CGM) reveals that approximately 80% of people eating a “healthy” diet have multiple daily glucose excursions above 140 mg/dL — the level associated with vascular and neurological damage — without any awareness. CGM metrics that predict long-term health outcomes better than HbA1c: time in range (TIR: 70-140 mg/dL, target above 90%), glucose variability (CV below 18%, standard deviation below 15 mg/dL), and peak postprandial glucose (target below 140 mg/dL at 1-hour). CGM-guided dietary modification reduces peak glucose by 30-50% in non-diabetic users within 2-4 weeks.
Why HbA1c Is Insufficient: The Case for CGM in Non-Diabetic Individuals
HbA1c — glycated hemoglobin, reflecting average blood glucose over approximately 90 days — is the standard clinical measure for diabetes screening and management. It is a 90-day average, and like all averages, it obscures the most clinically important information: the peaks and valleys, the timing, the duration of hyperglycemia, and the frequency of low glucose episodes. A person can have an HbA1c of 5.4% (ostensibly normal) while experiencing daily glucose excursions to 180-200 mg/dL after meals, spending significant time above 140 mg/dL, and exhibiting the glucose variability pattern associated with progressive vascular damage — none of which is captured in the A1c average.
The Continuous Glucose Monitoring (CGM) literature has produced several paradigm-shifting insights. Mazze et al. and the landmark Diabetes Control and Complications Trial extension (DCCT/EDIC) established that glucose variability — not just average glucose — predicts microvascular complications in diabetics. Ceriello et al. (2008, Diabetes Care) demonstrated that postprandial glucose spikes produce endothelial dysfunction through oxidative stress (8-isoprostane, nitrotyrosine generation) that persists for hours after glucose returns to baseline — the “glycemic memory” or “metabolic legacy” effect. Cavalot et al. (2011, Journal of Clinical Endocrinology and Metabolism) found postprandial glucose was a stronger predictor of cardiovascular events than fasting glucose or HbA1c in a 10-year prospective study of type 2 diabetics.
For non-diabetic individuals, the Continuous Glucose Monitoring in Non-Diabetic Participants (CGMNP) literature — led by researchers at Stanford (Sonnenburg Lab) and the Weizmann Institute (Eran Segal, David Zeevi) — has been equally revealing. Zeevi et al. (2015, Cell — n=800, non-diabetic) demonstrated that glycemic responses to identical meals varied dramatically between individuals, with some subjects showing marked glucose excursions to foods considered “healthy” (e.g., white rice causing minimal excursion in one person but 200+ mg/dL response in another). These interindividual differences were predicted by microbiome composition, meal timing, sleep quality, pre-meal glucose, and other factors — not by calorie content or glycemic index tables. This work established that personalized glycemic responses can only be identified through individual CGM use, not population tables.
Key CGM Metrics and Their Clinical Significance
Time in Range (TIR): target above 90% within 70-140 mg/dL. TIR is the most clinically meaningful CGM metric — the percentage of time blood glucose remains within the target range. For non-diabetic individuals, the target range is 70-140 mg/dL; diabetic targets are 70-180 mg/dL. Lacy et al. (2020, Lancet Diabetes and Endocrinology) demonstrated in type 2 diabetics that each 10% increase in TIR correlated with reduced risk of retinopathy, nephropathy, and neuropathy. In non-diabetics, TIR below 90% indicates significant glycemic dysfunction requiring dietary or lifestyle intervention. The International Consensus on Time in Range (2019) recommends reporting TIR, time above range (TAR), and time below range (TBR) as the primary CGM endpoints.
Glucose variability (CV and SD): target CV below 18%, SD below 15 mg/dL. Glucose variability — measured as coefficient of variation (CV, the SD divided by the mean, expressed as percentage) — reflects the amplitude and frequency of glucose oscillations. CV above 36% defines labile glucose control in diabetics; for non-diabetics, CV above 18-20% suggests significant metabolic dysregulation. Standard deviation above 15-20 mg/dL indicates wide glucose swings. The mechanism of harm from glucose variability is oxidative stress oscillation: each spike and trough generates ROS, endothelial activation, and the glycemic memory phenomenon. Monnier et al. (2006, JAMA) established that glucose variability was a stronger predictor of oxidative stress markers than mean glucose in diabetics — the same mechanism applies in non-diabetics at lower absolute values.
Peak postprandial glucose: target below 140 mg/dL at 60 minutes post-meal. The 140 mg/dL threshold is not arbitrary — it corresponds to the glucose level above which beta cell first-phase insulin secretion begins to fail (impaired first-phase response is the earliest detectable functional defect in pre-diabetes), endothelial eNOS activity is suppressed, and oxidative stress markers begin to rise. Consistently exceeding 140 mg/dL after meals — even if average glucose is normal — is the earliest CGM marker of progressive insulin resistance. The international standard for defining “normal” glycemic response in clinical research is peak glucose remaining below 140 mg/dL at 1-hour postprandial.
Fasting glucose and dawn phenomenon: target 70-89 mg/dL fasting. Fasting glucose reflects hepatic insulin resistance (elevated gluconeogenesis) more than peripheral muscle insulin resistance. The “dawn phenomenon” — cortisol-driven hepatic glucose output in the early morning hours (5-8 AM), producing rising glucose before breakfast — is measurable on CGM and reflects HPA axis timing and cortisol amplitude. Fasting glucose above 95 mg/dL with the dawn phenomenon pattern suggests early hepatic insulin resistance. Optimal fasting glucose for longevity and insulin sensitivity: 72-89 mg/dL (Coutinho et al., 2002, Diabetes Care — n=95,783 showed linear relationship between fasting glucose and cardiovascular risk starting at 75 mg/dL).
Post-meal area under the curve (AUC) and glucose return to baseline. The time required for postprandial glucose to return to pre-meal baseline reflects insulin secretion adequacy and peripheral glucose uptake (insulin sensitivity). Metabolically healthy individuals return to baseline within 60-90 minutes of peak. Extended postprandial hyperglycemia (glucose remaining elevated 2-3 hours after meals) indicates impaired second-phase insulin secretion and/or reduced peripheral glucose uptake — a pattern predictive of type 2 diabetes development years before fasting glucose becomes abnormal.
Available CGM Devices for Non-Diabetic Users
Until 2024, CGM devices required a prescription in the US. The Dexterity Stelo (Abbott Libre Rio predecessor) and Dexterity/Abbott Libre Stelo became the first CGMs approved for over-the-counter non-prescription use for non-diabetic individuals in 2024. Options as of 2025-2026:
Abbott Libre Stelo: OTC availability, 14-day wear sensor, interstitial glucose reading every 15 minutes (5-minute with latest firmware), Bluetooth to smartphone app, no fingerstick calibration required. Accuracy: MARD (mean absolute relative difference) of approximately 8-9% versus venous glucose — adequate for trend monitoring and dietary optimization. Cost: approximately $49-89 per sensor/14-day period without insurance.
Dexterity Stelo: Similar OTC availability, 15-day sensor, competitive accuracy to Libre Stelo. Provides CGM metrics in app format compatible with health platforms.
Levels Health subscription service: Prescription CGM (Libre 3 or Dexcom G7) with AI-powered food logging, coaching, and personalized metabolic scoring. Provides the most interpretive guidance for non-diabetic optimization but at higher cost ($200-400/month). Best choice for individuals who want comprehensive support alongside the data.
Dexcom G7 (prescription): The most accurate consumer CGM, MARD approximately 8.2%, 10-day wear, with the most comprehensive third-party app integration. Requires prescription but telehealth services (Function Health, Levels, HLTH Code) facilitate access for non-diabetic wellness users.
CGM-Guided Dietary Optimization Protocol
The primary value of CGM for non-diabetic users is personalized dietary optimization — identifying which specific foods, combinations, and timing patterns produce the highest glucose excursions in that individual, then systematically modifying them. A structured 2-4 week CGM-guided protocol:
Week 1: Baseline characterization. Eat normally and observe. Log all meals with photos using the CGM app, note sleep duration and quality (poor sleep raises fasting glucose 15-20 mg/dL), and track exercise timing and intensity. After 7 days, identify: (1) which meals produce the highest peak glucose, (2) foods or combinations that consistently exceed 140 mg/dL, (3) the dawn phenomenon pattern (rising glucose 5-8 AM before breakfast), and (4) the TIR and CV baseline metrics.
Weeks 2-4: Targeted modification. Apply the high-yield interventions validated in CGM research, observing the effect in real time: food sequencing (Shukla et al., 2015, Diabetes Care — consuming fiber and protein first, carbohydrates last, reduces postprandial glucose 29-37%); post-meal walks (Colberg et al., 2009, Diabetes Care — 15-minute walk within 30 minutes of eating reduces postprandial glucose 12-17% through AMPK-mediated GLUT4 translocation); carbohydrate substitution (replace highest-excursion refined carbs with lower-glycemic alternatives — observe individual response, which may differ substantially from population tables); meal timing (moving the largest carbohydrate meals to morning when insulin sensitivity is highest; see our circadian rhythm optimization protocol); and apple cider vinegar (Johnston et al., 2004, JAMA — 20g ACV before a high-carbohydrate meal reduces postprandial glucose 19-34% through acetic acid inhibition of salivary amylase and improved insulin sensitivity).
Nutritional interventions with CGM-measurable effects. The following interventions have been validated in CGM trials or reliable RCTs with postprandial glucose as the primary endpoint: berberine 500mg before carbohydrate meals (reduces postprandial glucose 20-30%, Zhang et al., 2008); cinnamon extract (0.5-2g Ceylon cinnamon, Kirkham et al. meta-analysis — 18-29% postprandial glucose reduction); magnesium glycinate 400mg/day (improves insulin sensitivity over weeks — measurable on CGM as lower baseline and reduced excursions); and resistant starch (green banana flour, cooked-cooled potato, pulse legumes — feeds SCFA-producing microbiota, improving insulin sensitivity over 2-4 weeks).
CGM and Exercise: The Metabolic Flexibility Window
CGM provides unprecedented visibility into exercise-glucose interactions. Zone 2 training (low-to-moderate intensity aerobic exercise) typically produces a modest glucose decrease during exercise and a rapid return to normal baseline — the signature of intact insulin-independent GLUT4 translocation. High-intensity training (HIIT, sprinting, heavy resistance exercise) often produces a paradoxical glucose rise due to catecholamine-driven hepatic glucose output, followed by a prolonged period of enhanced insulin sensitivity and glucose uptake for 12-24 hours (the “EPOC glucose window”). Post-exercise hypoglycemia can occur in individuals on insulin or sulfonylureas — CGM provides early warning of dangerous drops.
For metabolic flexibility assessment on CGM: a metabolically flexible individual shows fasting glucose of 72-89 mg/dL upon waking (having been burning fat overnight), minimal dawn phenomenon, postprandial glucose returning to baseline within 60-90 minutes of meals, and glucose dropping appropriately during moderate exercise. A metabolically inflexible individual shows fasting glucose above 95 mg/dL (impaired overnight fat burning with compensatory hepatic glucose output), marked dawn phenomenon, postprandial glucose remaining elevated 2-3 hours, and a paradoxical glucose rise during moderate exercise. See our metabolic flexibility training protocol for the intervention approach.
Frequently Asked Questions
Q: Do I need a CGM if I’m not diabetic?
CGM provides information that cannot be obtained through any other currently available non-invasive means. The Zeevi et al. (2015) study demonstrated that individual glycemic responses to identical foods vary dramatically — population averages (glycemic index tables, calorie counts) do not predict individual responses. A 2-4 week CGM observation period provides personalized data on which foods spike your glucose, how your fasting pattern looks, how exercise affects your response, and how sleep quality alters your metabolic state the following day. This is information of genuine preventive value — identifying patterns of impaired glucose regulation decades before HbA1c or fasting glucose become abnormal.
Q: What is the target blood sugar after eating?
For non-diabetic individuals, evidence-based postprandial targets: below 140 mg/dL at 60 minutes (maximum), returning to pre-meal baseline within 90 minutes. The 140 mg/dL threshold is where oxidative stress, endothelial dysfunction, and impaired first-phase insulin secretion begin. Many functional medicine practitioners and longevity physicians use a more aggressive target of below 120 mg/dL at 60 minutes to optimize for long-term vascular protection. Consistently exceeding 140 mg/dL despite dietary modification is an indication for further metabolic investigation.
Q: Does a CGM reading of 150 mg/dL mean I have diabetes?
A single reading above 150 mg/dL is not diagnostic of diabetes. Diabetes diagnosis requires: fasting glucose above 126 mg/dL on two occasions, 2-hour postprandial above 200 mg/dL during an OGTT, random glucose above 200 mg/dL with symptoms, or HbA1c above 6.5%. A CGM excursion to 150 mg/dL after a large carbohydrate meal in a non-diabetic individual is abnormal in the sense that a metabolically healthy response should remain below 140 mg/dL — but it indicates metabolic dysregulation worth addressing, not a diabetes diagnosis. The pattern over time — TIR, frequency of excursions, return-to-baseline kinetics — is more informative than any individual reading.
Q: Can CGM data be inaccurate?
CGM measures interstitial fluid glucose, which lags behind blood glucose by 5-15 minutes during rapid glucose changes (rising or falling). This lag is clinically significant during exercise and immediately postprandially — the CGM peak may appear 15-20 minutes after the actual blood glucose peak and return to baseline slightly delayed. Additionally, accuracy degrades with compression artifact (lying on the sensor), rapid temperature changes, and during the first 24 hours of sensor placement as the tissue response settles. MARD values of 8-9% for consumer CGMs mean that a reading of 140 mg/dL could accurately reflect 127-153 mg/dL. For clinical decision-making in diabetes management, these limitations matter considerably; for dietary optimization in non-diabetics, CGM remains the most valuable available tool despite these constraints.
CGM-guided metabolic optimization is one of the highest-yield preventive tools available for identifying early glucose dysregulation, personalizing dietary choices, and objectively measuring the impact of lifestyle interventions in real time. If you are interested in a structured CGM protocol, metabolic flexibility assessment, or functional medicine evaluation of your glucose patterns, contact our office at (810) 206-1402 to discuss the options available to you.